Cargando…

Acute glycemic control in diabetics. How sweet is oprimal? Con: Just as sweet as in nondiabetic is better

This review is for Con side of “Pro-Con debate” on the optimal target of blood glucose levels in patients with chronic hyperglycemia (e.g. premorbid HbA1c level > 7%). Currently, international guideline recommended that blood glucose level ≤ 180 mg/dL in critically ill patients irrespective of pr...

Descripción completa

Detalles Bibliográficos
Autor principal: Egi, Moritoki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219026/
https://www.ncbi.nlm.nih.gov/pubmed/30410766
http://dx.doi.org/10.1186/s40560-018-0337-1
_version_ 1783368568358830080
author Egi, Moritoki
author_facet Egi, Moritoki
author_sort Egi, Moritoki
collection PubMed
description This review is for Con side of “Pro-Con debate” on the optimal target of blood glucose levels in patients with chronic hyperglycemia (e.g. premorbid HbA1c level > 7%). Currently, international guideline recommended that blood glucose level ≤ 180 mg/dL in critically ill patients irrespective of presence or absence of premorbid diabetes. However, there are several studies to generate the hypothesis that liberal glycemic control (e.g., target blood glucose level 180–250 mg/dL) may be beneficial in critically ill patients with premorbid hyperglycemia. Although there is before-after study to report its safety and feasibility, it should be noted that this strategy may have a potential to increase the risk of infection, glycosuria, and polyneuropathy. Furthermore, there is randomized controlled study which showed the potential harm of liberal glycemic control in patients with premorbid hyperglycemia. Additionally, there are lots of uncertainty about the candidate and methodology of such a permissive hyperglycemia. With considering these facts, it might be better to keep target of blood glucose level in patients with diabetes the same as patients without diabetes (≤ 180 mg/dL), until randomized control study as like LUCID (the Liberal GlUcose Control in Critically Ill Patients with Pre-existing Type 2 Diabetes) trial will justify its risk and benefit.
format Online
Article
Text
id pubmed-6219026
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-62190262018-11-08 Acute glycemic control in diabetics. How sweet is oprimal? Con: Just as sweet as in nondiabetic is better Egi, Moritoki J Intensive Care Review This review is for Con side of “Pro-Con debate” on the optimal target of blood glucose levels in patients with chronic hyperglycemia (e.g. premorbid HbA1c level > 7%). Currently, international guideline recommended that blood glucose level ≤ 180 mg/dL in critically ill patients irrespective of presence or absence of premorbid diabetes. However, there are several studies to generate the hypothesis that liberal glycemic control (e.g., target blood glucose level 180–250 mg/dL) may be beneficial in critically ill patients with premorbid hyperglycemia. Although there is before-after study to report its safety and feasibility, it should be noted that this strategy may have a potential to increase the risk of infection, glycosuria, and polyneuropathy. Furthermore, there is randomized controlled study which showed the potential harm of liberal glycemic control in patients with premorbid hyperglycemia. Additionally, there are lots of uncertainty about the candidate and methodology of such a permissive hyperglycemia. With considering these facts, it might be better to keep target of blood glucose level in patients with diabetes the same as patients without diabetes (≤ 180 mg/dL), until randomized control study as like LUCID (the Liberal GlUcose Control in Critically Ill Patients with Pre-existing Type 2 Diabetes) trial will justify its risk and benefit. BioMed Central 2018-11-06 /pmc/articles/PMC6219026/ /pubmed/30410766 http://dx.doi.org/10.1186/s40560-018-0337-1 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Egi, Moritoki
Acute glycemic control in diabetics. How sweet is oprimal? Con: Just as sweet as in nondiabetic is better
title Acute glycemic control in diabetics. How sweet is oprimal? Con: Just as sweet as in nondiabetic is better
title_full Acute glycemic control in diabetics. How sweet is oprimal? Con: Just as sweet as in nondiabetic is better
title_fullStr Acute glycemic control in diabetics. How sweet is oprimal? Con: Just as sweet as in nondiabetic is better
title_full_unstemmed Acute glycemic control in diabetics. How sweet is oprimal? Con: Just as sweet as in nondiabetic is better
title_short Acute glycemic control in diabetics. How sweet is oprimal? Con: Just as sweet as in nondiabetic is better
title_sort acute glycemic control in diabetics. how sweet is oprimal? con: just as sweet as in nondiabetic is better
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219026/
https://www.ncbi.nlm.nih.gov/pubmed/30410766
http://dx.doi.org/10.1186/s40560-018-0337-1
work_keys_str_mv AT egimoritoki acuteglycemiccontrolindiabeticshowsweetisoprimalconjustassweetasinnondiabeticisbetter